Samer Al Hadidi, Associate Professor at UAMS – University of Arkansas for Medical Sciences, shared a thread post on X:
“My top 8 Myeloma/Amyloidosis ASH25 abstracts:
1. CARTITUDE-4 longer follow up ~ 3yrs : (Abstract 297774 – Luciano J Costa)
In ITT population, pts with standard-risk cytogenetics had a 2.5 years PFS rate of 71% in the cilta-cel arm vs 43% in control arm.
Only data on standard risk presented, high risk outcomes likely inferior.
Read the full article.
2. UK-MRA RADAR: Isa-VRDc for Ultra-High-Risk MM (Abstract 299709 – Ramasamy et al.)
Primary endpoint MET: 88% alive & PF at 18 mo (vs 66% expected)
≥VGPR: 96% at 6mo post-consolidation, MRD negativity: 69.5% post-ASCT
Read the full article.
3. COBRA: KRd vs VRd Head-to-Head (Abstract 298836 – Dytfeld et al.)
MRD-neg CR (10⁻⁵): 31% vs 18% (p=0.016)
PFS: NR vs 49 mo (HR 0.57, p=0.0095)
CR: 71% vs 53% (p=0.005)
More neutropenia and cardiac evens with KRd , less neuropathy.
Read the full article.
4. IFM2021-01 TECLILLE: Tec-Dara in Elderly NDMM (Abstract 298743 – Manier et al.)
78% ≥VGPR after 4 cycles, ORR at best response: 100%!
MRD-neg (10⁻⁶): 51% ITT, 100% in evaluable pts at 6mo
PFS/OS: 100% at median 7.6mo FU
Grade ≥3 AE 76%, infections 14%, all pts got IVIG
Read the full article.
5. GC012F/AZD0120: Dual BCMA/CD19 CAR-T in NDMM (Abstract 291409 – Du et al.)
Next-day manufacturing + first-line use
ORR: 100%, sCR: 97%, MRD negativity: 100% across all doses!, 30-month PFS: 88%, OS: 92%, 81.5% sustained MRD-neg >12mo
CRS 33% (all grade 1-2), NO ICANS!
Read the full article.
6. KTX-1001: First MMSET Inhibitor (Abstract 290722 – Saad Z. Usmani)
First-in-class oral MMSET/NSD2 inhibitor shows promise
ORR: 40% showed response/SD in heavily pretreated RRMM: Responses: 1 VGPR (10+ mo), 1 PR (4+ mo), 12 SD (2-20+ mo) Median 6.5 prior lines; 42.5% prior BCMA CAR-T
Grade ≥3 in 77.5% (thrombocytopenia 30%, neutropenia 30%)
Read the full article.
7. Etentamig in AL Amyloidosis (Abstract 299514 – Raj Chakraborty)
BCMA bispecific tackles AL with remarkable depth of response
Hematologic response: 100%, ≥VGPR: 100%, CR: 83%, Median time to CR: 0.9 months, Cardiac response: 30%, Renal response: 67%
CRS 17% (all grade 1), NO ICANS, limited cytopenias
Read the full article.
8. LimiTec: Limited Duration Teclistamab (Abstract 292744 – Razzo et al. Al Garfall)
Can we stop bispecifics after deep response? Early data says YES!
6-mo FFP: 77%, 12-mo FFP: 73%
Similar outcomes in prior BCMA-directed therapy pts
Talquetamab rescue worked in 3/3 pts
Read the full article.
Looking forward a productive meeting, we may have some LBAs to add as well as more interesting data once presented at the meeting.“
More posts featuring Samer Al Hadidi.